Etodolac is a prescription nonsteroidal anti-inflammatory drug (NSAID) specifically formulated to manage pain and inflammation associated with osteoarthritis and rheumatoid arthritis. Its unique pharmacologic profile offers effective symptomatic relief while demonstrating a potentially lower incidence of certain gastrointestinal adverse effects compared to some older NSAIDs. Clinicians value etodolac for its balanced efficacy and tolerability in chronic inflammatory conditions.

Features

• Active ingredient: Etodolac
• Available in tablet and extended-release tablet formulations
• Selective COX-2 inhibitor with relative COX-1 sparing properties
• Multiple strength options (400mg, 500mg, 600mg tablets; 400mg, 500mg, 600mg extended-release)
• Bioavailability of approximately 80% following oral administration
• Peak plasma concentration within 1-2 hours (standard release); 5-7 hours (extended release)
• Plasma half-life of approximately 7 hours
• Extensive hepatic metabolism via cytochrome P450 system
• Renal excretion as primary elimination pathway

Benefits

• Provides effective relief from inflammatory pain and stiffness associated with arthritis
• Demonstrates preferential COX-2 inhibition, potentially reducing gastrointestinal complications
• Maintains analgesic and anti-inflammatory effects for extended durations with appropriate dosing
• Offers flexible dosing regimens tailored to individual patient needs and severity
• Improves joint function and mobility in chronic arthritic conditions
• Reduces morning stiffness and enables improved daily functioning

Common use

Etodolac is primarily indicated for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. It is prescribed to reduce pain, tenderness, swelling, and stiffness in affected joints. Healthcare providers may also consider etodolac off-label for other painful inflammatory conditions when NSAID therapy is appropriate. The medication works by inhibiting prostaglandin synthesis through preferential inhibition of cyclooxygenase-2 (COX-2), thereby reducing inflammation and pain perception at the site of injury or arthritis.

Dosage and direction

For osteoarthritis: The recommended starting dose is 800-1200mg daily in divided doses. Maintenance doses typically range from 600-1200mg daily divided into 2-4 doses. Maximum daily dose should not exceed 1200mg for osteoarthritis.

For rheumatoid arthritis: The recommended dose is 800-1200mg daily in divided doses. Doses may be adjusted based on individual response and tolerability, not to exceed 1200mg daily.

Extended-release tablets: Usually administered as 400-1000mg once daily. Tablets should be swallowed whole and not crushed, chewed, or divided.

Administration with food or antacids may minimize gastrointestinal discomfort. Dosage should be individualized to the lowest effective dose for the shortest duration consistent with treatment goals.

Precautions

Patients should be monitored for signs of gastrointestinal ulceration and bleeding, particularly those with history of peptic ulcer disease. Regular assessment of renal function is recommended, especially in elderly patients or those with pre-existing renal impairment. Hepatic function should be monitored during prolonged therapy. Caution is advised in patients with hypertension, heart failure, or edema as NSAIDs may cause fluid retention. Patients should be advised to report any signs of skin rash, mucosal lesions, or allergic reactions immediately. Use with caution in patients with asthma, especially those with aspirin-sensitive asthma.

Contraindications

Etodolac is contraindicated in patients with known hypersensitivity to etodolac or other NSAIDs. It should not be used in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Contraindicated in the setting of coronary artery bypass graft (CABG) surgery pain management. Should not be used in patients with active peptic ulcer disease or gastrointestinal bleeding. Avoid use in patients with severe heart failure, advanced renal disease, or severe hepatic impairment. Not recommended during the third trimester of pregnancy.

Possible side effect

Common side effects (≥1%) include dyspepsia (10-15%), nausea (7-10%), abdominal pain (5-8%), diarrhea (5-7%), flatulence (3-5%), headache (5-8%), and dizziness (3-5%). Less frequent adverse effects include peripheral edema (2-4%), hypertension (2-3%), and rash (2-3%). Serious side effects requiring immediate medical attention include gastrointestinal bleeding (incidence approximately 1%), peptic ulceration, renal impairment, hepatic toxicity, and severe skin reactions. Cardiovascular thrombotic events may occur with long-term use.

Drug interaction

Etodolac may increase the risk of bleeding when used with anticoagulants like warfarin. Concurrent use with other NSAIDs or aspirin may increase the risk of gastrointestinal adverse effects. May reduce the antihypertensive effect of ACE inhibitors, angiotensin II receptor blockers, and beta-blockers. Can decrease the natriuretic effect of furosemide and thiazides. May increase lithium levels and risk of lithium toxicity. Concomitant use with corticosteroids increases the risk of gastrointestinal ulceration. Methotrexate levels may be increased, enhancing toxicity risk. Cyclosporine nephrotoxicity may be enhanced when used with etodolac.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Patients should be educated on maintaining consistent dosing intervals for optimal therapeutic effect while avoiding potential toxicity from dose accumulation.

Overdose

Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, hypertension, acute renal failure, respiratory depression, and coma. Management is supportive and symptomatic. There is no specific antidote. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may be effective in reducing absorption. Hemodialysis is not effective due to high protein binding. Forced diuresis, alkalinization of urine, or hemodialysis are not expected to be useful. Support blood pressure and maintain renal function with appropriate fluid management.

Storage

Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Keep in original container with lid tightly closed. Protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers as this may affect stability. Extended-release tablets should be protected from crushing or breaking.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Etodolac is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary. Patients should consult their healthcare provider for personalized medical advice, including potential risks and benefits specific to their medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this product information.

Reviews

Clinical studies demonstrate etodolac’s efficacy in managing arthritis symptoms, with many patients reporting significant improvement in pain scores and functional status. In comparative trials, etodolac has shown similar efficacy to other NSAIDs with a potentially favorable gastrointestinal tolerability profile. Patient satisfaction surveys indicate improved quality of life measures, particularly regarding reduced morning stiffness and improved mobility. Long-term studies support maintained effectiveness with appropriate monitoring. Healthcare providers frequently note the balance between anti-inflammatory efficacy and tolerability makes etodolac a valuable option in arthritis management protocols.